Product Description
Overall, the global coronary chronic total occlusion guidewire market was valued at $72.7 million in 2025. This is expected to increase over the forecast period at a CAGR of 2.2% to reach $84.9 million.
The full report suite on the global market for coronary chronic total occlusion guidewire includes specialized guidewires used in percutaneous coronary intervention (PCI) to navigate and treat chronic total occlusions (CTOs) in coronary arteries.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Market Drivers & Limiters
- Market Forecasts Until 2031, and Historical Data to 2021
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Global Coronary Chronic Total Occlusion Guidewire Market Trends

A key growth driver in the CTO guidewire market is its complementary use with IVL. As IVL is one of the fastest-growing segments in interventional cardiology, its adoption is providing additional, supportive growth for CTO guidewires.
Global Coronary Chronic Total Occlusion Guidewire Market Share Insights

- Asahi Intecc was the leading company in the CTO guidewire market in 2025. Its portfolio includes the Corsair® and Tornus® CTO device lines, as well as the Gaia™, Fielder™, Ultimate™ and Miracle™ CTO guidewire product lines. The company is expected to maintain its market share throughout the reporting period.
- Boston Scientific ranked as the second-leading company in the CTO guidewire market in 2025. Its portfolio includes the SENTAI™ Guidewire Family, a line of specialized guidewires designed to navigate complex coronary chronic total occlusions effectively. While the company holds significant market shares across multiple segments, CTO represents a lower strategic priority, which may result in a potential loss of market share over the reporting period.
- Abbott was a notable competitor in the global CTO guidewire market in 2025. The company’s HI-TORQUE INFILTRAC™ and INFILTRAC™ PLUS guidewires are specialized devices designed to aid the penetration of chronic total occlusions (CTOs) during coronary interventions. As a global company with a strong presence across multiple markets, Abbott’s market share is expected to remain stable over the reporting period.
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.